Puma Biotechnology can be a compelling opportunity for aggressive risk-tolerant investors looking at small-cap oncology equities, as its commercialized drug Nerlynx provides baseline revenues. However, biotech investments carry inherent binary clinical risks and regulatory hurdles, making thorough portfolio risk management essential.